PFE Pfizer Inc

   By Stephen Nakrosis 
 

Pfizer Inc. (PFE) on Friday said European Union regulators recommended its Talzenna be granted marketing authorization in the EU.

The company said the positive opinion was issued by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

The indication adopted is for the use of Talzenna to treat certain adult breast cancer patients.

Pfizer said the positive opinion was "based on results from largest Phase 3 trial performed to date of a PARP inhibitor in gBRCA-mutated advanced breast cancer."

The committee's opinion will now be reviewed by the European Commission, Pfizer said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

April 26, 2019 11:50 ET (15:50 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.